Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402)
Douglas W. Sborov, Anuj K. Mahindra, Vera J. Suman, Elisabet Esteve Manasanch, Prashant Kapoor, Tibor Kovacsovics, Cesar Rodriguez, Benjamin Parsons, Jose Eugenio Najera, Lyle Goldman, Destin Carlisle, Yujia Wen, Shira H. Dinner, Ilene A. Galinsky, LeAnne Kennedy, James Omel, Philip McCarthy, Saad Usmani, Paul G. Richardson Blood Cancer Journal
· Springer Nature
· 2026-11-16
· DOI: 10.1038/s41408-026-01674-w
Аннотация
Blood Cancer Journal, Published online: 16 November 2026; doi:10.1038/s41408-026-01674-w Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402)
Douglas W. Sborov, Anuj K. Mahindra, Vera J. Suman, Elisabet Esteve Manasanch, Prashant Kapoor, Tibor Kovacsovics et al. Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402). // Blood Cancer Journal. – 2026. – DOI: 10.1038/s41408-026-01674-w. – URL: https://www.nature.com/articles/s41408-026-01674-w
Douglas W. Sborov, Anuj K. Mahindra, Vera J. Suman, Elisabet Esteve Manasanch, Prashant Kapoor, Tibor Kovacsovics, Cesar Rodriguez, Benjamin Parsons, Jose Eugenio Najera, Lyle Goldman, Destin Carlisle, Yujia Wen, Shira H. Dinner, Ilene A. Galinsky, LeAnne Kennedy, James Omel, Philip McCarthy, Saad Usmani, & Paul G. Richardson (2026). Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402). Blood Cancer Journal. https://doi.org/10.1038/s41408-026-01674-w
Douglas W. Sborov, et al. “Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402).” Blood Cancer Journal, 2026. doi:10.1038/s41408-026-01674-w.
@article{Sborov2026,
title = {Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402)},
author = {Sborov, Douglas W. and Mahindra, Anuj K. and Suman, Vera J. and Manasanch, Elisabet Esteve and Kapoor, Prashant and Kovacsovics, Tibor and Rodriguez, Cesar and Parsons, Benjamin and Najera, Jose Eugenio and Goldman, Lyle and Carlisle, Destin and Wen, Yujia and Dinner, Shira H. and Galinsky, Ilene A. and Kennedy, LeAnne and Omel, James and McCarthy, Philip and Usmani, Saad and Richardson, Paul G.},
journal = {Blood Cancer Journal},
year = {2026},
doi = {10.1038/s41408-026-01674-w},
url = {https://www.nature.com/articles/s41408-026-01674-w}
}
ABSTRACT Diagnosing and classifying platelet disorders (PD) is challenging in children. Therefore, we evaluated clinical, laboratory, and genetic data to improve current algorithms by performing a prospective observational cohort study...
Abstract Background and Objectives Perioperative blood transfusion in hip arthroplasty is associated with increased morbidity, prolonged hospitalization, and higher costs. This study aimed to identify independent risk factors and...